EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tirzepatide Ameliorates Renal Dysfunction, Dyslipidemia, and Thyroid Hormone Dysregulation in Diabetic Rats

Amal M. AlRashidi, Ahmad H. Alhowail

International Journal of Pharmacology · 28.04.2026 · 22 (2)

DOI: 10.31083/ijp49432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmacology, online erschienen am 28.04.2026. Verfasst von Amal M. AlRashidi und 1 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qassim University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tirzepatide (TZP), a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP-1) receptor agonist, has shown potential in improving glycemic control. However, its effects on diabetes mellitus (DM)-related systemic complications remain less defined. This study investigated the impact of TZP on metabolic, cardiovascular, renal, and thyroid parameters in a rat model of DM.

Methods

Experimental DM was induced in rats via a single intraperitoneal injection of streptozotocin (50 mg/kg). Animals were allocated into four groups: control (saline), DM, TZP alone (1.35 mg/kg, cyclic dosing), and DM+TZP (streptozotocin followed by five TZP injections). Survival, body-weight, and serum biochemical markers were monitored, including glucose, insulin, troponin I, Creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine, cholesterol, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), thyroid-stimulating hormone (TSH), thyroxine (T4), and triiodothyronine (T3).

Results

Survival was preserved in the control, TZP alone, and DM+TZP groups, whereas mortality reached 10% in the DM group. Body weight decreased significantly in the DM and DM+TZP groups, with a modest reduction in the TZP alone group. TZP markedly increased hyperglycemia and LDH levels without altering troponin I or CK-MB levels. DM-associated elevations in BUN and creatinine were partially attenuated by TZP, suggesting renoprotective effects. TZP had no impact on cholesterol or LDL-C, but significantly decreased triglycerides and increased HDL-C. Additionally, TZP modulated thyroid hormone levels, as reflected by increased T4 and decreased T3 concentrations compared with diabetic rats.

Conclusions

In this experimental DM model, TZP improved glycemic control, ameliorated renal dysfunction, and favorably modulated lipid metabolism and thyroid axis activity, with no evidence of overt myocardial necrosis observed based on troponin I and CK-MB; additional studies incorporating histology and/or functional assessments are needed to evaluate subclinical cardiac effects. These findings indicate the therapeutic potential of TZP in mitigating DM-associated complications beyond glucose regulation.

Förderung

  • Qassim University

Zitieren

APA

AlRashidi, A. M., & Alhowail, A. H. (2026). Tirzepatide Ameliorates Renal Dysfunction, Dyslipidemia, and Thyroid Hormone Dysregulation in Diabetic Rats. International Journal of Pharmacology, 22(2). https://doi.org/10.31083/ijp49432

Vancouver

AlRashidi AM, Alhowail AH. Tirzepatide Ameliorates Renal Dysfunction, Dyslipidemia, and Thyroid Hormone Dysregulation in Diabetic Rats. International Journal of Pharmacology. 2026;22(2). doi:10.31083/ijp49432

BibTeX
@article{AlRashidi2026,
  author = {AlRashidi, Amal M. and Alhowail, Ahmad H.},
  title = {Tirzepatide Ameliorates Renal Dysfunction, Dyslipidemia, and Thyroid Hormone Dysregulation in Diabetic Rats},
  journal = {International Journal of Pharmacology},
  year = {2026},
  volume = {22},
  number = {2},
  doi = {10.31083/ijp49432}
}
Kostenlos starten →